Tarsus Pharmaceuticals (TARS) Amortization of Deferred Charges (2019 - 2026)

Tarsus Pharmaceuticals' Amortization of Deferred Charges history runs 8 years deep, the most recent figure standing at $159000.0 for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 14.39% year-over-year to $159000.0 in Q1 2026; TTM through Mar 2026 was $613000.0, a 20.91% increase from a year earlier, with the FY2025 full-year figure at $593000.0, up 47.51% from the prior year.
• Amortization of Deferred Charges grew to $159000.0 in Q1 2026 per TARS's latest filing, from $156000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $295000.0 in Q4 2023 and bottomed at -$96000.0 in Q4 2022.
• The 5-year median for Amortization of Deferred Charges is $114000.0 (2024), against an average of $95705.9.
• Across the five-year window, Amortization of Deferred Charges slumped 132.65% in 2022 and soared 407.29% in 2023, its largest moves.
• Year by year, Amortization of Deferred Charges stood at -$96000.0 in 2022, then surged by 407.29% to $295000.0 in 2023, then slumped by 53.22% to $138000.0 in 2024, then increased by 13.04% to $156000.0 in 2025, then climbed by 1.92% to $159000.0 in 2026.
• Per Business Quant, the three latest TARS Amortization of Deferred Charges figures stand at $159000.0 (Q1 2026), $156000.0 (Q4 2025), and $152000.0 (Q3 2025).